niraparib + ipilimumab

Niraparib + ipilimumab is a combination therapy under investigation primarily for maintenance treatment in patients with advanced pancreatic cancer who have not progressed after platinum-based chemotherapy. Niraparib is an orally active, selective poly (ADP-ribose) polymerase (PARP) inhibitor that targets PARP-1 and PARP-2, enzymes involved in DNA repair. By inhibiting these enzymes, niraparib induces synthetic lethality in tumor cells with homologous recombination deficiencies, such as those harboring BRCA mutations[5][6]. Ipilimumab is a monoclonal antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), thereby enhancing T-cell activation and promoting antitumor immune responses[8]. Preclinical studies suggest that combining PARP inhibition with immune checkpoint blockade can enhance antitumor activity by increasing DNA damage and immunogenicity of tumor cells[3]. This combination has shown promising progression-free survival benefits as maintenance therapy for advanced pancreatic cancer in phase Ib/II clinical trials[2][3].

Other names

niraparib + ipilimumab